RAPID ACCESS TO PREVENTIVE INTERVENTION DEVELOPMENT - “RAPID” - ADDENDUM

Release Date:  July 13, 2000

NOTICE:  CA-00-021

National Cancer Institute

Investigators are hereby notified that the receipt date for requests for 
RAPID resources has been changed to November 21, 2000.  Investigators are 
further notified that the website for the RAPID initiative has been updated, 
see http://dcp.nci.nih.gov/CB/. 

The Rapid Access to Preventive Intervention Development (RAPID) makes 
available to academic investigators the preclinical and early clinical drug 
development contract resources of NCI’s Division of Cancer Prevention. The 
goal of RAPID is the rapid movement of novel molecules and concepts from the 
laboratory to the clinic for clinical trials of efficacy.  RAPID will assist 
investigators who submit successful requests by providing any (or all) of the 
pre-clinical and phase 1 clinical developmental requirements for phase 2 
clinical efficacy trials. These include, for example, preclinical 
pharmacology, toxicology, and efficacy studies;  bulk supply, GMP 
manufacturing, and formulation;  and regulatory and IND support and phase 1 
clinical studies.

INQUIRIES:

Inquiries are encouraged, and the opportunity to clarify issues or answer 
questions is welcome. Inquiries may be directed to:
		
RAPID
c/o James A. Crowell, Ph.D.
Division of Cancer Prevention, NCI
Executive Plaza North, Suite 200B
6130 Executive Blvd., Rockville, MD 20852 (overnight mail)
9000 Rockville Pike, Bethesda, MD 20892 (regular mail)
Telephone (301) 496-8563
Fax (301) 402-0553
email inquiries to:  jc94h@nih.gov

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files.